Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income from Continuing Operations (2023 - 2025)

CG Oncology filings provide 3 years of Income from Continuing Operations readings, the most recent being 41256000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 29.72% to 41256000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 160843000.0, a 82.69% decrease, with the full-year FY2025 number at 160843000.0, down 82.69% from a year prior.
  • Income from Continuing Operations hit 41256000.0 in Q4 2025 for CG Oncology, up from 43708000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 8675000.0 in Q1 2023 to a low of 43708000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 3 years was 19656500.0 (2024), compared with a mean of 24785500.0.
  • The widest YoY moves for Income from Continuing Operations: up 29.72% in 2025, down 119.05% in 2025.
  • CG Oncology's Income from Continuing Operations stood at 16551000.0 in 2023, then crashed by 92.16% to 31804000.0 in 2024, then decreased by 29.72% to 41256000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 41256000.0 (Q4 2025), 43708000.0 (Q3 2025), and 41422000.0 (Q2 2025) per Business Quant data.